Home » News » Students News » Pharmaceutical Treatment of Pre-School ADHD is Ineffective


Pharmaceutical Treatment of Pre-School ADHD is Ineffective

By Senior News Editor
Reviewed by John M. Grohol, Psy.D. on March 10, 2013

Pharmaceutical Treatment of Pre-School ADHD is Ineffective Emerging research suggests that many young children with moderate to severe attention-deficit/hyperactivity disorder (ADHD) continue to have significant symptoms despite treatment.

The finding is salient as ADHD is becoming a more common diagnosis in early childhood.

Researchers found that 9 out of 10 young children with moderate to severe attention-deficit/hyperactivity disorder (ADHD) continue to experience serious to severe symptoms and impairment long after their original diagnoses and treatment.

The study, published in the Journal of the American Academy of Child and Adolescent Psychiatry was led by investigators at Johns Hopkins Children’s Center. Researchers say the investigation is the largest long-term analysis to date of preschoolers with ADHD.

Experts say the research provides significant insight light on the natural course of a condition that is being diagnosed at an increasingly earlier age.

Understanding how ADHD progresses in this age group is critical, says lead researcher Mark Riddle, M.D., a pediatric psychiatrist.

“We found that ADHD in preschoolers is a chronic and rather persistent condition, one that requires better long-term behavioral and pharmacological treatments than we currently have.”

The study shows that nearly 90 percent of the 186 youngsters followed continued to struggle with ADHD symptoms six years after diagnosis; children taking ADHD medication had just as severe symptoms as those who were medication-free.

Children with ADHD, ages 3 to 5, were enrolled in the study and treated for several months, after which they were referred to community pediatricians for ongoing care.

Over the next six years, the researchers used detailed reports from parents and teachers to track the children’s behavior, school performance, and the frequency and severity of three of ADHD’s hallmark symptoms—inattention, hyperactivity, and impulsivity.

In addition, children had full diagnostic workups by the study’s clinicians at the beginning, halfway through, and at the end of the research.

Medication did not appear to make a difference in more than two-thirds of children as symptom severity scores did not differ significantly between children on medication and those off medication.

Specifically, 62 percent of children taking anti-ADHD drugs had clinically significant hyperactivity and impulsivity, compared with 58 percent of those not taking medicines.

And 65 percent of children on medication had clinically significant inattention, compared with 62 percent of their medication-free counterparts.

However, investigators caution that it remains unclear whether the lack of medication effectiveness was due to suboptimal drug choice or dosage, poor adherence, medication ineffectiveness per se, or some other reason.

“Our study was not designed to answer these questions, but whatever the reason may be, it is worrisome that children with ADHD, even when treated with medication, continue to experience symptoms, and what we need to find out is why that is and how we can do better,” Riddle explained.

Children who had oppositional defiant disorder or conduct disorder in addition to ADHD were 30 percent more likely to experience persistent ADHD symptoms six years after diagnosis, compared with children whose sole diagnosis was ADHD.

“ADHD is considered a neurobehavioral condition and is marked by inability to concentrate, restlessness, hyperactivity and impulsive behavior, and can have profound and long-lasting effects on a child’s intellectual and emotional development,” Riddle added.

“It can impair learning, academic performance, peer and family relationships, and even physical safety. Past research has found that children with ADHD are at higher risk for injuries and hospitalizations.”

According to the researchers, more than 7 percent of U.S. children are currently treated for ADHD, and the economic burden of the condition is estimated to be between $36 billion and $52 billion annually.

Source: Elsevier

Child not paying attention to his homework photo by shutterstock.

 

APA Reference
Nauert, R. (2013). Pharmaceutical Treatment of Pre-School ADHD is Ineffective. Psych Central. Retrieved on September 16, 2014, from http://psychcentral.com/news/2013/03/10/pharmaceutical-treatment-of-pre-school-adhd-is-ineffective/52346.html